Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

Exclusion Criteria

• •Evidence of relapsed/recurrent/residual disease as assessed by bone marrow aspirate and biopsy performed between days 30-60 after HSCT
• •Active acute graft vs host disease requiring an equivalent dose of \> 0.5 mg/kg/day of prednisone or equivalent or those patients which necessitated the addition of another agent for the treatment of GVHD beyond corticosteroids
• •Ongoing uncontrolled infection
• •Cardiac disease: congestive heart failure \> class II NYHA, unstable angina or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months
• •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
• •Uncontrolled hypertension
• •Known HIV infection or chronic hepatitis B or C
• •Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
• •Pulmonary hemorrhage/bleeding event \> CTCAE v 4.0 Grade 2 within 4 weeks of starting study drug
• •Any other hemorrhage/bleeding event \> CTCAE v. 4.0 Grade 3 within 4 weeks of starting study drug
• •Serious non-healing wound, non-healing ulcer, or bone fracture
• •Evidence or history of bleeding diathesis or coagulopathy
• •Major surgery or significant traumatic injury within 4 weeks of starting study drug
• •Use of St. John's Wort or rifampin (rifampicin)
• •Known or suspected allergy to sorafenib
• •Pregnant or breast-feeding
• •Receiving any other investigational agents